Home
Live Updates
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis : comparemela.com
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...
Related Keywords
,
Daniel Alkon ,
Robert Weinstein ,
Alan Tuchman ,
Nemoursai Dupont ,
Exchange Commission ,
Drug Administration ,
Nasdaq ,
Synaptogenix Inc ,
Cleveland Clinic ,
Chief Scientific ,
Orphan Drug Designation ,
Private Securities Litigation Reform Act ,
Autistic Spectrum Disorder Deficits ,
Media Contacts ,
Synaptogenix ,
Nc ,
comparemela.com © 2020. All Rights Reserved.